Updates are available Correction dated 2020-04-08
Click to view Correction: https://doi.org/10.1007/s00392-020-01620-1
-
Authors
Böhm, Michael
Townsend, Raymond R.
Kario, Kazuomi
Kandzari, David
Mahfoud, Felix
Weber, Michael A.
Schmieder, Roland E.
Tsioufis, Konstantinos
Hickey, Graeme L.
Fahy, Martin
DeBruin, Vanessa
Brar, Sandeep
Pocock, Stuart
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02439749 at ClinicalTrials.govDocuments that mention this clinical trial
One-Year Outcomes in “Real-World” Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study [PE-Plus PAS])
https://doi.org/10.1016/j.amjcard.2015.11.043
Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design
https://doi.org/10.1007/s00392-020-01595-z
The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications
https://doi.org/10.1016/j.ahj.2015.08.021
-
Funding
Funding for this research was provided by:
Medtronic
- License Information
-
More Information
Article History
Received: 19 November 2019
Accepted: 2 January 2020
First Online: 7 February 2020
Change Date: 8 April 2020
Change Type: Correction
Change Details: The original version of this article unfortunately contained a mistake.
Compliance with ethical standards
:
: Prof. Böhm and Prof. Mahfoud are supported by the Deutsche Forschungsgemeinschaft (SFB, Aachen - Homburg, TRR 219, S01). Prof. Böhm: Consultant fees from Bayer AG, Abbott Vascular, Amgen, AstraZeneca, Boehringer Ingelheim, Servier, Medtronic, Vifor, and Novartis. Dr. Townsend: Consultant fees from Medtronic. Dr. Weber: consultant to Medtronic, ReCor, Ablative Solutions, Boston Scientific, Novartis, Bristol-Myers Squibb and Abbvie. Dr. Kandzari: Grant support from Medtronic, Boston Scientific Corporation, and Biotronik; and consultant fees from Medtronic, Biotronik, and CSI. Prof. Mahfoud: supported by Deutsche Hochdruckliga, Deutsche Gesellschaft für Kardiologie and Deutsche Forschungsgemeinschaft and has received speakers honoraria from Medtronic and ReCor. Prof Kario: Grant support from A & D, MSD K.K., Asteras Pharma, Otsuka Pharmaceutical, Otsuka holdings, Omron Healthcare, Sanwakagaku Kenkyusho, Daiichi Sankyo Co., Sumitomo, Dainippon pharma, Takeda Pharmaceutical, Teijin Pharma, Japan Boehringer Ingerheim, Pfizer, Fukuda lifetec, Dukuda Denshi, Bristol-Myers Squibb, Mocida Pharmaceutical and Roche Diagnostic; and consultant fees from Idorsia, Omron Healthcare, Daiichi Sankyo, and Terumo Medical Corporation. Prof Schmieder: Grant support from Medtronic, ReCor, and Ablative Solutions; and consultant fees from Medtronic and ReCor. Dr. Tsioufis: Grant support from St. Jude Medical and Recordatti; and consultant fees from Medtronic, Servier, Bayer AG, Menarini, Novartis, AstraZeneca, Boehringer Ingelheim, Pfizer, Chiesi, Pharmanel, Sanofi-Aventis, Amgen, and ELPEN. Dr. Hickey, Mr. Fahy, Ms. DeBruin, and Dr. Brar are full-time employees and shareholders of Medtronic. Prof. Pocock: Nothing to disclose.
